BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bolt Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.04+0.04 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.71 (−29.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Bolt Biotherapeutics, Inc. grew revenue 12.8% to $4.70M over the twelve months to Jun 30, 2026. Free cash flow was -$39.92M.
Revenue
$4.70M
+12.8% vs. a year earlier
Operating income
-$30.76M
TTM Q2 2026
Free cash flow
-$39.92M
FY2025
EPS, diluted
-$16.44
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.83M
- P/E ratio
- –
- Price to sales
- 1.45
- Price to book
- 0.54
- Dividend yield
- –
- Free cash flow yield
- -584.53%
Fundamentals
- Revenue
- $4.70M
- Net income
- -$28.74M
- EPS, diluted
- -$16.44
- Free cash flow
- -$39.92M
- Book value per share
- $7.48
- Diluted shares
- 2M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$4.70M+12.8% YoY
Operating income
-$30.76M
Net income
-$28.74M
EPS, diluted
-$16.44
Free cash flow
–
Reported periodTrailing twelve months